Objective, To study the clinical spectrum of Behcet's disease (BD) in child
hood, and to report our experience of using thalidomide.
Method. Ten children, diagnosed with BD, were studied retrospectively.
Results. The median (range) age at first presentation was 4 (1.2-12.0) yr,
at diagnosis was 11 (3-15) yr and the follow-up period was 4.1 (0.6-6.3) yr
. Oral ulcers were present in all patients (100%), genital ulcers were pres
ent in six (60%), peri-anal ulcers were present in three (30%), skin manife
stations were present in nine (90%), intracranial hypertension was present
in two (20%), mild gastrointestinal symptoms were present in five (50%), jo
int symptoms were present in six (60%), ocular lesions were present in five
(50%), but only one child had anterior and posterior uveitis. Therapeutica
lly, a range of drugs was used, including colchicine, that resulted in good
responses in five children. Thalidomide (1 mg/kg/week to 1 mg/kg/day) was
used in five children who were unresponsive to other immunosuppressive agen
ts. It resulted in complete remission in three children and less frequent m
ilder oral ulcers in two. Neuropathy developed in two children and in one i
t was irreversible.
Conclusion. BD in children is similar to the disease in adults. Thalidomide
provided a useful therapeutic option for severe oral and genital ulceratio
n which was unresponsive to other therapies. Awareness of the danger of axo
nal neuropathy and teratogenesis at all times during thalidomide therapy is
crucial. A low dose is probably as effective as higher doses.